» Articles » PMID: 26833129

Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas

Overview
Journal Cancer Res
Specialty Oncology
Date 2016 Feb 3
PMID 26833129
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Dysregulation of MYC expression is a hallmark of cancer, but the development of agents that target MYC has remained challenging. The oncogenic MUC1-C transmembrane protein is, like MYC, aberrantly expressed in diverse human cancers. The present studies demonstrate that MUC1-C induces MYC expression in KRAS mutant non-small cell lung cancer (NSCLC) cells, an effect that can be suppressed by targeting MUC1-C via shRNA silencing, CRISPR editing, or pharmacologic inhibition with GO-203. MUC1-C activated the WNT/β-catenin (CTNNB1) pathway and promoted occupancy of MUC1-C/β-catenin/TCF4 complexes on the MYC promoter. MUC1-C also promoted the recruitment of the p300 histone acetylase (EP300) and, in turn, induced histone H3 acetylation and activation of MYC gene transcription. We also show that targeting MUC1-C decreased the expression of key MYC target genes essential for the growth and survival of NSCLC cells, such as TERT and CDK4. Based on these results, we found that the combination of GO-203 and the BET bromodomain inhibitor JQ1, which targets MYC transcription, synergistically suppressed MYC expression and cell survival in vitro as well as tumor xenograft growth. Furthermore, MUC1 expression significantly correlated with that of MYC and its target genes in human KRAS mutant NSCLC tumors. Taken together, these findings suggest a therapeutic approach for targeting MYC-dependent cancers and provide the framework for the ongoing clinical studies addressing the efficacy of MUC1-C inhibition in solid tumors.

Citing Articles

Feature Selection and Network-Driven Analyses to Unveil Common RNA Signatures in Colon and Pancreatic KRAS-Mutant Cancers.

Pane K, Zanfardino M, Grimaldi A, Leone I, Nuzzo S, Salvatore M Cancer Med. 2025; 14(5):e70468.

PMID: 40013338 PMC: 11865888. DOI: 10.1002/cam4.70468.


The Role of MUC1 in Renal Cell Carcinoma.

Milella M, Rutigliano M, Lasorsa F, Ferro M, Bianchi R, Fallara G Biomolecules. 2024; 14(3).

PMID: 38540735 PMC: 10967890. DOI: 10.3390/biom14030315.


MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.

Haratake N, Ozawa H, Morimoto Y, Yamashita N, Daimon T, Bhattacharya A J Thorac Oncol. 2023; 19(3):434-450.

PMID: 37924972 PMC: 10939926. DOI: 10.1016/j.jtho.2023.10.017.


MUC1 attenuates neutrophilic airway inflammation in asthma by reducing NLRP3 inflammasome-mediated pyroptosis through the inhibition of the TLR4/MyD88/NF-κB pathway.

Liu L, Zhou L, Wang L, Mao Z, Zheng P, Zhang F Respir Res. 2023; 24(1):255.

PMID: 37880668 PMC: 10601133. DOI: 10.1186/s12931-023-02550-y.


Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody.

Fang J, Lai S, Yu H, Ma L Antibodies (Basel). 2023; 12(3).

PMID: 37489369 PMC: 10366937. DOI: 10.3390/antib12030047.


References
1.
Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett J, Obaya A . Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A. 2000; 97(5):2229-34. PMC: 15783. DOI: 10.1073/pnas.050586197. View

2.
Raina D, Agarwal P, Lee J, Bharti A, McKnight C, Sharma P . Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One. 2015; 10(8):e0135156. PMC: 4534190. DOI: 10.1371/journal.pone.0135156. View

3.
Huang L, Ren J, Chen D, Li Y, Kharbanda S, Kufe D . MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther. 2003; 2(6):702-6. View

4.
Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G . A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004; 6(4):308-18. DOI: 10.1038/ncb1110. View

5.
Leder A, Pattengale P, Kuo A, Stewart T, Leder P . Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell. 1986; 45(4):485-95. DOI: 10.1016/0092-8674(86)90280-1. View